Kết quả điều trị phác đồ M-dcf trong ung thư biểu mô thực quản giai đoạn di căn tại bệnh viện đại học y hà nội

To evaluate the treatment results of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (m-DCF) in patients with metastatic esophageal cancer at Hanoi Medical University Hospital in the period of 2019 and 2022. Patients and methods: Descriptive, retrospective study on 42 metastatic esophageal cancer patients treated with m-DCF at Hanoi Medical University Hospital from August 2019 to June 2022. Results: Patient Characteristics: The average age was 57.1±7.4. Both patients were male. Pre-treatment status PS predominantly was 0 or 1 with a rate of 97.6%. Almost patients (95.2%) with a history of alcohol and/or tobacco use. Grade II squamous cell carcinoma was predominant. Treatment outcomes: The response rate was 61.9%, the complete response rate was 4.8%, the partial response rate was 57.1%, and the clinical benefit rate was 85.7%. Median PFS was 6 months. Median OS was 13 months The regimen was well tolerated, the most common side effect of the therapy was neutropenia, mainly in grades 2 or 3. Other side effects were mainly encountered in grades 1 or 2. Conclusion: m-DCF chemotherapy regimen appears tolerable and highly effective for metastatic esophageal cancer patients.